Antiplatelet and direct oral anticoagulation management after coronary artery bypass graft surgery: the Cinderella of current cardiovascular trials, please show me (some) evidence

European Heart Journal
This commentary discusses dual pathway inhibition therapy (DPI; aspirin + low dose direct oral anticoagulant) post coronary artery bypass graft surgery. The authors summarise available data, noting limited data in this specific patient cohort and call for further research.

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy

Cochrane Database of Systematic Reviews
This review of 34 studies (n=1960) found the available evidence does not support the superiority of any anticoagulant to another. Further studies are needed to identify patient populations in which CRRT should commence with no pharmacological anticoagulation or with citrate.

Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis

Thorax
This meta-analysis of 102 studies (n=64503) found patients admitted to the ICU for severe COVID-19 had a high risk of VTE. Further studies are needed to determine the specific effects of COVID-19 on the risk of thrombosis in less severe forms of the disease.

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services